Sang-Hyun Park1, Kim M O'Connor, Harry McKellop. 1. J Vernon Luck Orthopaedic Research Center, Orthopaedic Hospital, 2400 South Flower Street, Los Angeles, CA 90007, USA. SPARK@laoh.ucla.edu
Abstract
OBJECTIVE: Evaluate the effects of axial motion and transforming growth factor beta (TGF-beta) on callus formation and fracture healing.DESIGN Prospective experimental design with a 39-day postfracture recovery. SETTING: Unrestricted cage activity with weight bearing as tolerated. ANIMALS: Twenty-two skeletally mature, female New Zealand White rabbits. INTERVENTIONS: Displaced, closed tibial fractures were reduced and stabilized in external fixators on the fourth day following fracture. Half of the fixators were locked for the duration of healing. The other fixators were locked for one week, then unlocked for the remaining four weeks. Half of the fractures in each fixator group received two injections of recombinant human TGF-beta1 (rhTGF-beta1). One injection was administered at the time of reduction, and the second was given 48 hours later. MAIN OUTCOME MEASUREMENTS: Interfragmentary axial motion was measured during floor activity. Biomechanical properties were measured during a torsion test to failure. Callus area and the distribution of tissues within the callus were determined by computer-aided histomorphometry. RESULTS: The administration of TGF-beta1 did not alter callus size, mechanical properties, or the distribution of tissues in the callus of fractures that were stabilized in locked external fixators. Recoverable axial motion fixation increased callus size, quantity of mineralized bone bridging the fracture, and maximum torque relative to locked fixation. The injection of TGF-beta1 negated the beneficial effects of axial motion by promoting the formation of a peripheral callus bridged by fibrous tissue rather than mineralized trabecular bone. CONCLUSIONS: Injection of rhTGF-beta1 during the first postfracture week does not provide a biologic boost that improves fracture healing. Injection of TGF-beta1 may be detrimental to healing under conditions when fracture motion is present. The results suggest that there is a tendency for exposure to TGF-beta1 to inhibit the normal development of peripheral callus in response to axial interfragmentary motion.
OBJECTIVE: Evaluate the effects of axial motion and transforming growth factor beta (TGF-beta) on callus formation and fracture healing.DESIGN Prospective experimental design with a 39-day postfracture recovery. SETTING: Unrestricted cage activity with weight bearing as tolerated. ANIMALS: Twenty-two skeletally mature, female New Zealand White rabbits. INTERVENTIONS: Displaced, closed tibial fractures were reduced and stabilized in external fixators on the fourth day following fracture. Half of the fixators were locked for the duration of healing. The other fixators were locked for one week, then unlocked for the remaining four weeks. Half of the fractures in each fixator group received two injections of recombinant humanTGF-beta1 (rhTGF-beta1). One injection was administered at the time of reduction, and the second was given 48 hours later. MAIN OUTCOME MEASUREMENTS: Interfragmentary axial motion was measured during floor activity. Biomechanical properties were measured during a torsion test to failure. Callus area and the distribution of tissues within the callus were determined by computer-aided histomorphometry. RESULTS: The administration of TGF-beta1 did not alter callus size, mechanical properties, or the distribution of tissues in the callus of fractures that were stabilized in locked external fixators. Recoverable axial motion fixation increased callus size, quantity of mineralized bone bridging the fracture, and maximum torque relative to locked fixation. The injection of TGF-beta1 negated the beneficial effects of axial motion by promoting the formation of a peripheral callus bridged by fibrous tissue rather than mineralized trabecular bone. CONCLUSIONS: Injection of rhTGF-beta1 during the first postfracture week does not provide a biologic boost that improves fracture healing. Injection of TGF-beta1 may be detrimental to healing under conditions when fracture motion is present. The results suggest that there is a tendency for exposure to TGF-beta1 to inhibit the normal development of peripheral callus in response to axial interfragmentary motion.
Authors: Cuicui Wang; Jie Shen; Kiminori Yukata; Jason A Inzana; Regis J O'Keefe; Hani A Awad; Matthew J Hilton Journal: Bone Date: 2014-12-16 Impact factor: 4.398
Authors: G Zimmermann; A Moghaddam; M Reumann; B Wangler; L Breier; A Wentzensen; P Henle; S Weiss Journal: Unfallchirurg Date: 2007-02 Impact factor: 1.000
Authors: Kambiz Sarahrudi; Anita Thomas; Mehdi Mousavi; Georg Kaiser; Julia Köttstorfer; Mathias Kecht; S Hajdu; S Aharinejad Journal: Injury Date: 2011-05-06 Impact factor: 2.586
Authors: Stefan Eipeldauer; Anita Thomas; Leonard Hoechtl-Lee; Mathias Kecht; Harald Binder; Julia Koettstorfer; Markus Gregori; Kambiz Sarahrudi Journal: PLoS One Date: 2014-12-11 Impact factor: 3.240
Authors: Masato Yuasa; Masanori Saito; Cesar Molina; Stephanie N Moore-Lotridge; Michael A Benvenuti; Nicholas A Mignemi; Atsushi Okawa; Toshitaka Yoshii; Herbert S Schwartz; Jeffry S Nyman; Jonathan G Schoenecker Journal: PLoS One Date: 2018-05-31 Impact factor: 3.240